<DOC>
	<DOCNO>NCT02960581</DOCNO>
	<brief_summary>This Phase 1 study evaluate safety , tolerability , pharmacokinetics anti-viral efficacy PGT121 monoclonal antibody HIV prevention therapy .</brief_summary>
	<brief_title>A Clinical Trial Safety , Pharmacokinetics Antiviral Activity PGT121 Monoclonal Antibody ( mAb ) HIV-uninfected HIV-infected Adults</brief_title>
	<detailed_description>This Phase 1 study evaluate safety , tolerability , pharmacokinetics anti-viral efficacy PGT121 monoclonal antibody HIV prevention therapy . PGT121 mAb recombinant human IgG1 monoclonal antibody target V3 glycan-dependent epitope region HIV envelope protein . PGT121 mAb chosen study potent , neutralizes wide array HIV virus , prevent treat simian-human immunodeficiency virus ( SHIV ) rhesus monkey .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Group 1 Willing maintain low risk behavior HIV infection Group 1 confirm HIVinfection , pregnancy lactation , significant acute chronic disease clinically significant laboratory abnormality Group 2 HIVinfected male females stable antiretroviral regimen HIV1 RNA plasma level &lt; 50 copies/ml , CD4 cell count &gt; 300 cells/uL CD4 nadir &gt; 200 cell/uL Group 2 history AIDSdefining illness , significant acute chronic medical condition HIV infection , clinically significant laboratory abnormality Group 3 HIVinfected male females antiretroviral therapy &gt; 6 month detectable HIV1 RNA plasma level 100 100,000 copies/ml , CD4 cell count &gt; 300 cells/uL CD4 nadir &gt; 200 cell/uL Group 3 history AIDSdefining illness , significant acute chronic medical condition HIV infection , clinically significant laboratory abnormality</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>